{
  "variants": [
    {
      "gene": "DJ1",
      "protein_change": "E64D",
      "variant_string": "DJ1 E64D",
      "functional_evidence": {
        "assay_types": [
          "Crystallography (protein structure analysis)",
          "Immunocytochemistry (protein localization)",
          "PET Imaging (clinical correlation)"
        ],
        "findings": {
          "protein_structure": "No significant structural differences observed compared to wild-type DJ1 (crystallography).",
          "protein_localization": "E64D showed altered subcellular localization (e.g., reduced nuclear localization compared to wild-type) in HEK293 and COS7 cells.",
          "protein_stability": "Reduced protein stability or expression levels in E64D carriers (implied by clinical correlation with EOPD).",
          "clinical_correlation": "E64D carriers exhibited reduced DAT availability (PET imaging), consistent with Parkinson's disease pathology."
        },
        "controls_used": {
          "wild_type": true,
          "other_mutants": true,
          "sibling_controls": true
        },
        "replicates": "Not explicitly stated, but functional assays (e.g., immunocytochemistry) compared E64D with L166P (from prior studies)."
      },
      "acmg_assessment": {
        "step_1": "Disease mechanism defined: DJ1 mutations cause autosomal recessive EOPD (PARK7).",
        "step_2": "Applicable assays: Standard techniques (crystallography, immunocytochemistry, PET) are widely accepted for studying protein function and disease correlation.",
        "step_3": {
          "substep_3a": "Controls and replicates: Limited explicit details on replicates, but functional comparisons with L166P (prior study) and sibling controls (no symptoms) suggest some control use.",
          "substep_3b": "Assay validation: Crystallography and immunocytochemistry are standard, validated techniques. PET imaging is a clinical gold standard for Parkinson's correlation."
        },
        "step_4": {
          "substep_4a": "Statistical analyses: No OddsPath values provided. Lack of explicit statistical metrics (e.g., p-values, effect sizes).",
          "substep_4b": "Control variants: Only E64D and L166P (from prior studies) mentioned, likely fewer than 10 controls total."
        },
        "final_strength": "PS3_moderate"
      },
      "clinical_implication": "E64D is likely pathogenic, contributing to EOPD (PARK7) due to altered protein localization and clinical correlation."
    },
    {
      "gene": "DJ1",
      "protein_change": "L166P",
      "variant_string": "DJ1 L166P",
      "functional_evidence": {
        "assay_types": [
          "Immunocytochemistry (from prior studies)"
        ],
        "findings": {
          "protein_localization": "L166P showed distinct subcellular localization compared to E64D (used as a control in this study)."
        },
        "controls_used": {
          "wild_type": true,
          "other_mutants": true
        },
        "replicates": "Not explicitly stated in this study."
      },
      "acmg_assessment": {
        "step_1": "Disease mechanism defined: DJ1 mutations cause autosomal recessive EOPD (PARK7).",
        "step_2": "Applicable assays: Immunocytochemistry is standard for studying protein localization.",
        "step_3": {
          "substep_3a": "Controls and replicates: Limited details, but L166P was compared to E64D (from this study).",
          "substep_3b": "Assay validation: Immunocytochemistry is a validated technique."
        },
        "step_4": {
          "substep_4a": "Statistical analyses: No OddsPath values provided. Lack of explicit statistical metrics.",
          "substep_4b": "Control variants: Only L166P and E64D (from this study) mentioned, likely fewer than 10 controls total."
        },
        "final_strength": "PS3_supporting"
      },
      "clinical_implication": "L166P (from prior studies) shows altered protein localization, supporting its pathogenicity. However, this study does not provide new functional data for L166P."
    }
  ]
}